CALGARY, May 23 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. (TSX:
ONC, NASDAQ: ONCY) (“Oncolytics”) today announced it has been granted Canadian
Patent 2,360,833 entitled “Reovirus for the Treatment of Cellular
Proliferative Disorders.” The claims describe the use of one or more
recombinant reoviruses to treat Ras-mediated proliferative disorders.
“This patent provides the Company with additional patent protection for
the use of reovirus compositions for cancers and other cellular proliferative
disorders in Canada,” said Mary Ann Dillahunty, Vice President of Intellectual
Property for Oncolytics.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of Phase I/II and Phase II
human trials using REOLYSIN(R), its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For
further information about Oncolytics please visit www.oncolyticsbiotech.com.
This news release contains forward-looking statements, within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including among others, the Company’s belief as to
the importance of the issuance of this patent, the safety and efficacy of the
reovirus, the Company’s expectations as to the potential applications of the
patented technology and other statements relating to anticipated developments
in the Company’s business and technologies, involve known and unknown risks
and uncertainties that could cause the Company’s actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer
treatment, the success and timely completion of clinical studies and trials,
uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the
Company’s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to
update these forward-looking statements.
SOURCE Oncolytics Biotech Inc.
Released May 23, 2008